Conocimiento del coste de los tratamientos dispensados desde el Servicio de Farmacia Hospitalaria y percepción del estado de salud / Knowledge of the cost of the treatments delivered from the Hospital Pharmacy Department and perception of the health status

Objetivo: Valorar la influencia del conocimiento del coste económico del tratamiento sobre la percepción del paciente de su estado de salud y la atención recibida en el Servicio de Farmacia Hospitalaria (SFH). Método: Durante un periodo de cuatro meses, de julio a octubre de 2009, se entrega una encuesta a todos los pacientes que acuden a recoger medicación al Servicio de Farmacia Hospitalaria (SFH), excepto a los que inician el tratamiento. A los pacientes que devuelven la encuesta principal cumplimentada en una visita posterior, se les hace entrega de la segunda parte, en la que se les informa del coste mensual de su tratamiento y se reformulan preguntas de la encuesta principal. Resultados: Son repartidas 682 encuestas, de las cuales son contestadas 240 (35,3%). Se entrega la segunda parte de la encuesta a 223 pacientes, de las que se devuelven 151 (22,1%). En general, los pacientes están satisfechos con el tratamiento (90,4%) y con la atención recibida en el SFH (95,4%), tienen un buen conocimiento del tratamiento (69,2%), se consideran cumplidores (59,2%%) y no suelen consultar al farmacéutico del SFH (17,5%). En el análisis de la satisfacción del paciente antes (7,75; DE: 1,90) y después de conocer el coste del tratamiento (7,80; DE: 1,91) no se han encontrado diferencias estadísticamente significativas, excepto en los pacientes derivados desde la Unidad de Enfermedades Infecciosas (p = 0,015), menos satisfechos tras conocer el coste. Conclusiones: No se ha podido relacionar el conocimiento del coste del tratamiento, en rasgos generales, con cambios en la actitud de los pacientes frente al mismo, siendo necesario el diseño de estudios más amplios. Asimismo, sería recomendable acometer los puntos de mejora detectados por los pacientes para elevar la calidad de la Atención Farmacéutica ofrecida (AU)

Objective: To assess the influence of the knowledge of the financial cost of the treatment and perception of the patient of his/her health status and the health care received from the Hospital Pharmacy Department (HPD). Method: During a four-month period, from July to October of 2009, a questionnaire was provided to all the patients coming to the Hospital Pharmacy Department to gather their medications, except for those starting their therapies. The patients returning the completed questionnaire at a next visit were provided with the second part, in which they were informed on the monthly cost of their treatments and some questions from the main questionnaire were asked again. Results: 682 questionnaires were provided, of which 240 (35.3%) were returned completed. 223 patients were given the second part, of which 151 (22.1%) were returned. In general, the patients were satisfied with their treatments (90.4%) and with the care provided at the HPD (95.4%), 69.2% had good knowledge of their treatment, and 59.2% considered themselves as good compliers, and 17.5% did not usually consult with the pharmacist at the HPD. The patient's satisfaction analysis before (7.75; SD: 1.90) and after knowing the treatment cost (7.80; SD: 1.91) did not show statistically significant differences, with the exception of those patients derived from the Infectious Disease Department (p = 0.015) that were less satisfied after knowing the cost. Conclusions: The knowledge on the treatment cost could not be related in general with changes in the attitude of the patients towards their treatments, being necessary the design of more profound studies. Besides, it should be recommended to undertake the improvement actions detected by the patients in order to increase the quality of the pharmacy care delivered (AU)

Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report.

WHAT IS KNOWN AND OBJECTIVE: Stiff-person syndrome (SPS) is an uncommon and disabling disorder characterized by progressive rigidity and episodic painful spasms involving axial and limb musculature. SPS treatment is mostly based on benzodiazepines, baclofen, immunosuppressants and intravenous immunoglobulin. Cannabis derivatives [tetrahydrocannabinol (THC) and cannabidiol (CBD)] are available as an oromucosal spray (Sativex(®)), indicated as add-on treatment, for symptom improvement in patients with moderate to severe spasticity because of multiple sclerosis (MS). Our objective is to report a case of seronegative SPS successfully treated with THC-CBD oromucosal spray. CASE SUMMARY: We report a case of a 40-year-old man presenting with progressive muscle stiffness and intermittent spasms for 6-years. The diagnosis of stiff-person syndrome was based on the clinical features and neuroelectrophysiologic findings of continuous motor unit activity. Glutamic acid decarboxylase autoantibodies was absent in our patient, in both serum and cerebrospinal fluid (CSF). Cannabis derivatives oromucosal spray was introduced after a series of unsatisfactory traditional medical treatments. After 14 months treated with THC-CBD oromucosal spray, improvement was verified in the eight dimensions of the scale of SF-36 quality of life questionnaire. WHAT IS NEW AND CONCLUSION: Clinical experience with cannabis derivatives in patients with multiple sclerosis is accumulating steadily, but there is no current literature about its efficacy for SPS. Because MS and SPS share some neurological symptoms such as spasticity and rigidity, it is thought that THC-CBC can be an option for SPS patient. Our case report suggests that THC-CBD oromucosal spray is an alternative treatment for patients with refractory SPS, and further validation is appropriate.

[The RICVAL study. Acute myocardial infarct in the city of Valencia. Data on 1,124 patients during the first twelve months of the registry (December, 1993--November, 1994)]. / Estudio RICVAL. El infarto agudo de miocardio en la ciudad de Valencia. Datos de 1,124 pacientes en los primeros 12 meses del Registro (diciembre de 1993-noviembre de 1994). Investigadores del RICVAL.

BACKGROUND AND OBJECTIVES: Information on the management of acute myocardial infarction in Spain is still scarce. The Register of Acute Myocardial Infarction of Valencia City (RICVAL) was established to collect, in a prospectively and uniformly way, data of patients with acute myocardial infarctions discharged from Valencia coronary care units, in order to obtain updated information on the management of these patients. Data of the first twelve months of the register are presented. METHODS: Using standardised variables, demographic, clinical, procedural and outcome data from patients with acute myocardial infarction were collected at the eight hospitals collaborating in the RICVAL, from 1 December 1993 to 30 November 1994. RESULTS: The eight participating hospitals cover 1,665,720 people. During 12 months, 1,124 patients were discharged from the participating coronary care units. Mean age was 65.1 years and 23.9% were female. The case fatality rate was 16.9%. Left ventricular failure (Killip 2, 3 and 4) was present in 42%. Thrombolytic therapy was applied in 43.5% with a median time delay of 210 minutes from chest pain onset. The delay time in initiating thrombolysis was longer in the women and in the elderly. CONCLUSION: Analysis of present data shows the feasibility of an acute myocardial infarction register in Valencia City. The RICVAL study will allow a better knowledge of demographic, clinical, procedural and outcome data in patients with myocardial infarction. The case fatality rate is still high when we consider that an acceptable level of thrombolytic therapy has been reached. The long delay time in initiating thrombolysis, particularly in the elderly and in the women, must be emphasized.

[Differential characteristics and survival of women with acute myocardial infarction. Registry of Acute Myocardial Infarctions of the City of Valencia (RICVAL). Researchers of the RICVAL]. / Características diferenciales y supervivencia del infarto agudo de miocardio en la mujer. Registro de infartos agudos de miocardio de la ciudad de Valencia (RICVAL). Investigadores del RICVAL.

INTRODUCTION AND OBJECTIVES: The prevalence of women who are admitted to the hospital after acute myocardial infarction is lower to that of men and their prognosis is worse. The reason for these differences is unclear. We studied the demographic and historical variables, the evolution, treatment and early survival in 269 women included in the Register of Acute Myocardial Infarctions of the City of Valencia (RICVAL) and compared them with the 855 men included in the same Register. PATIENTS AND METHODS: Register of patients admitted into a Coronary Care Unit in the City of Valencia since December, 1st, 1993 until November 30th, 1994. RESULTS: 23.9% of the patients were women with a mean age of 71.9 +/- 9 years; 46.8% of them were diabetics, 55.4% hypertensives, and 6.7% smokers. The women arrived for treatment later than men and 34.9% of them were thrombolised. The incidence in women of severe heart failure (Killip III and IV) was 40.1% and the mortality 29.7%. In women with thrombolytic treatment the mortality was 29.8%. In the logistic regression model performed, female sex predicted a higher mortality rate (odds ratio [OR] = 1.30; confidence interval [CI], 1.05-1.61). CONCLUSIONS: Early mortality in women after acute myocardial infarction is higher than in men in the RICVAL Register. The longer delay in initiating medical care and thrombolysis might be the cause for the higher proportion of heart failure among women and explain their worse prognosis after an acute myocardial infarction compared to men.